As of 2022, around ** percent of all Humira U.S. sales are expected to be at risk due to the drug patent expiring in 2023. This statistic illustrates the share of sales at risk of pharmaceutical products in the U.S. due to approaching drug patent expiries.
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Learn more about how Statista can support your business.
Evaluate Vantage. (May 25, 2022). Sales share of leading pharmaceutical products at risk in the U.S. due to approaching drug patent expiries between 2022 and 2028 [Graph]. In Statista. Retrieved June 26, 2025, from https://www.statista.com/statistics/1315621/sales-share-at-risk-of-top-drugs-due-to-us-patent-expiries/
Evaluate Vantage. "Sales share of leading pharmaceutical products at risk in the U.S. due to approaching drug patent expiries between 2022 and 2028." Chart. May 25, 2022. Statista. Accessed June 26, 2025. https://www.statista.com/statistics/1315621/sales-share-at-risk-of-top-drugs-due-to-us-patent-expiries/
Evaluate Vantage. (2022). Sales share of leading pharmaceutical products at risk in the U.S. due to approaching drug patent expiries between 2022 and 2028. Statista. Statista Inc.. Accessed: June 26, 2025. https://www.statista.com/statistics/1315621/sales-share-at-risk-of-top-drugs-due-to-us-patent-expiries/
Evaluate Vantage. "Sales Share of Leading Pharmaceutical Products at Risk in The U.S. Due to Approaching Drug Patent Expiries between 2022 and 2028." Statista, Statista Inc., 25 May 2022, https://www.statista.com/statistics/1315621/sales-share-at-risk-of-top-drugs-due-to-us-patent-expiries/
Evaluate Vantage, Sales share of leading pharmaceutical products at risk in the U.S. due to approaching drug patent expiries between 2022 and 2028 Statista, https://www.statista.com/statistics/1315621/sales-share-at-risk-of-top-drugs-due-to-us-patent-expiries/ (last visited June 26, 2025)
Sales share of leading pharmaceutical products at risk in the U.S. due to approaching drug patent expiries between 2022 and 2028 [Graph], Evaluate Vantage, May 25, 2022. [Online]. Available: https://www.statista.com/statistics/1315621/sales-share-at-risk-of-top-drugs-due-to-us-patent-expiries/
